Rituximab for Pediatric Renal Transplant Rejection

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT00697996
Phase
PHASE2/PHASE3
Status
Completed

Conditions

  • Kidney Transplantation

Eligibility Criteria

Sex
ALL
Age
5 Years - 21 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University

Key Dates

Start date
Jun 30, 2005
Status verified
Dec 2008
Completion
Aug 31, 2007

Study Design

Enrollment
20 participants
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Rituximab safety in pediatric patients

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By research site
Stanford University School of Medicine· Stanford, CA

Related Studies